Could a daily brain zapping helmet ease autism symptoms in kids?

NCT ID NCT07276555

Not yet recruiting Symptom relief Sponsor: Neurocytonix, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will test whether a device called NeuroCytotron, which sends low-energy magnetic pulses to specific brain areas, can safely improve social communication and reduce repetitive behaviors in children with autism. 256 children aged 3 to 12 will be randomly assigned to receive either real or sham (placebo) treatments for 28 days. Neither the families nor the researchers will know who gets the real treatment, and the main goal is to see if the active group shows greater improvement on standard autism rating scales.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NeuroCytotron device (low-energy pulsed electromagnetic fields)
What this could lead to: If it works, this could offer a new, noninvasive treatment option to ease core autism symptoms like social communication difficulties and repetitive behaviors in children.
What could go wrong: This is an early-stage trial with no prior human data, so the treatment may not work better than placebo. Risks include discomfort from lying still, anxiety, and possible side effects from sedation needed for MRI scans.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTISM SPECTRUM DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autism spectrum disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AUTISM SPECTRUM DISORDER

Contacts and locations

Locations

NeuroCytonix Mexico

San Pedro Garza García, Nuevo León, 66224, Mexico
NeuroCytonix, Inc.

Rockville, Maryland, 20850, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.